Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Free Report) traded up 9.7% on Thursday . The company traded as high as $13.39 and last traded at $13.44. 455,832 shares traded hands during mid-day trading, a decline of 65% from the average session volume of 1,298,486 shares. The stock had previously closed at $12.25.
Ginkgo Bioworks Stock Up 12.9 %
The company has a market capitalization of $795.24 million, a P/E ratio of -1.06 and a beta of 1.09. The business’s fifty day moving average is $10.08.
Institutional Investors Weigh In On Ginkgo Bioworks
Several institutional investors and hedge funds have recently made changes to their positions in DNA. KBC Group NV acquired a new stake in Ginkgo Bioworks during the 4th quarter worth $31,000. Palumbo Wealth Management LLC bought a new position in shares of Ginkgo Bioworks in the 4th quarter worth $144,000. SG Americas Securities LLC acquired a new position in Ginkgo Bioworks in the fourth quarter valued at about $199,000. Point72 Asia Singapore Pte. Ltd. lifted its stake in Ginkgo Bioworks by 644.5% in the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 32,319 shares of the company’s stock valued at $263,000 after buying an additional 27,978 shares during the period. Finally, FNY Investment Advisers LLC boosted its holdings in Ginkgo Bioworks by 125.6% during the fourth quarter. FNY Investment Advisers LLC now owns 75,966 shares of the company’s stock worth $745,000 after buying an additional 42,298 shares during the last quarter. Institutional investors and hedge funds own 78.63% of the company’s stock.
Ginkgo Bioworks Company Profile
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
Recommended Stories
- Five stocks we like better than Ginkgo Bioworks
- What is the Nasdaq? Complete Overview with History
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- P/E Ratio Calculation: How to Assess Stocks
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.